# Amlexanox for Type 2 Diabetes and Obesity

> **NCT01842282** · PHASE2 · TERMINATED · sponsor: **University of Michigan** · enrollment: 7 (actual)

## Conditions studied

- Diabetes Mellitus Type 2
- Non Alcoholic Fatty Liver Disease
- Obesity

## Interventions

- **DRUG:** Amlexanox

## Key facts

- **NCT ID:** NCT01842282
- **Lead sponsor:** University of Michigan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-07-19
- **Primary completion:** 2014-02-25
- **Final completion:** 2014-02-25
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Due to limited funding, trial was suspended, intending to restart with additional funds; then preliminary results were obtained, and research moved on to placebo controlled trial. Results for both have been published.
- **Last updated:** 2024-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01842282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01842282, "Amlexanox for Type 2 Diabetes and Obesity". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01842282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*